EE200000446A - Follikulaarsete lümfoomide ravi lümfotoksiini (LT) raja inhibiitorite abil - Google Patents

Follikulaarsete lümfoomide ravi lümfotoksiini (LT) raja inhibiitorite abil

Info

Publication number
EE200000446A
EE200000446A EEP200000446A EEP200000446A EE200000446A EE 200000446 A EE200000446 A EE 200000446A EE P200000446 A EEP200000446 A EE P200000446A EE P200000446 A EEP200000446 A EE P200000446A EE 200000446 A EE200000446 A EE 200000446A
Authority
EE
Estonia
Prior art keywords
inhibitors
lymphotoxin
pathway
treatment
follicular lymphomas
Prior art date
Application number
EEP200000446A
Other languages
English (en)
Inventor
L. Browning Jeffrey
Thorbecke Jeanette
Tsiagbe Vincent
Original Assignee
Biogen, Incorporated
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, New York University filed Critical Biogen, Incorporated
Publication of EE200000446A publication Critical patent/EE200000446A/et
Publication of EE05235B1 publication Critical patent/EE05235B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000446A 1998-01-30 1999-01-29 Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine EE05235B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (2)

Publication Number Publication Date
EE200000446A true EE200000446A (et) 2001-08-15
EE05235B1 EE05235B1 (et) 2009-12-15

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000446A EE05235B1 (et) 1998-01-30 1999-01-29 Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine

Country Status (24)

Country Link
EP (1) EP1051187B9 (et)
JP (2) JP4713733B2 (et)
KR (1) KR100622960B1 (et)
CN (1) CN1287853C (et)
AT (1) ATE253930T1 (et)
AU (1) AU752710B2 (et)
BR (1) BR9908214A (et)
CA (1) CA2319698A1 (et)
CZ (1) CZ301026B6 (et)
DE (1) DE69912743T2 (et)
DK (1) DK1051187T3 (et)
EA (1) EA003862B1 (et)
EE (1) EE05235B1 (et)
ES (1) ES2211035T3 (et)
HU (1) HU226044B1 (et)
IL (2) IL137489A0 (et)
IS (1) IS2254B (et)
NO (1) NO328116B1 (et)
NZ (1) NZ506529A (et)
PL (1) PL203279B1 (et)
PT (1) PT1051187E (et)
SK (1) SK285725B6 (et)
TR (2) TR200101693T2 (et)
WO (1) WO1999038525A1 (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201804A2 (en) * 1999-06-28 2002-09-28 Basf Ag Method for preventing tumoral growth
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
MXPA03003144A (es) 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN1678625A (zh) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
CA2496048A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
ATE253930T1 (de) 2003-11-15
AU752710B2 (en) 2002-09-26
NO328116B1 (no) 2009-12-14
IS2254B (is) 2007-06-15
DE69912743D1 (de) 2003-12-18
HUP0102363A2 (hu) 2001-10-28
HU226044B1 (en) 2008-03-28
JP2002501902A (ja) 2002-01-22
HUP0102363A3 (en) 2004-04-28
IL137489A (en) 2010-05-31
EP1051187A1 (en) 2000-11-15
BR9908214A (pt) 2000-11-28
PT1051187E (pt) 2004-03-31
NO20003848D0 (no) 2000-07-27
EA003862B1 (ru) 2003-10-30
CZ20002751A3 (cs) 2000-12-13
IS5570A (is) 2000-07-21
NZ506529A (en) 2002-12-20
TR200002203T2 (tr) 2000-12-21
PL342063A1 (en) 2001-05-21
ES2211035T3 (es) 2004-07-01
SK285725B6 (sk) 2007-07-06
KR20010040497A (ko) 2001-05-15
CA2319698A1 (en) 1999-08-05
JP4713733B2 (ja) 2011-06-29
DK1051187T3 (da) 2004-03-08
CZ301026B6 (cs) 2009-10-14
CN1289252A (zh) 2001-03-28
KR100622960B1 (ko) 2006-09-12
EP1051187B9 (en) 2004-08-11
IL137489A0 (en) 2001-07-24
WO1999038525A1 (en) 1999-08-05
TR200101693T2 (tr) 2002-06-21
JP2010235621A (ja) 2010-10-21
CN1287853C (zh) 2006-12-06
DE69912743T2 (de) 2004-09-23
EP1051187B1 (en) 2003-11-12
SK11302000A3 (sk) 2001-01-18
HK1029944A1 (en) 2001-04-20
AU2348899A (en) 1999-08-16
NO20003848L (no) 2000-10-02
PL203279B1 (pl) 2009-09-30
EE05235B1 (et) 2009-12-15
EA200000798A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
EA200101166A1 (ru) Ингибиторы металлопротеаз
MY169308A (en) Treatment of tnf? related disorders
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
DK0986382T3 (da) RAF-kinasehæmmere
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
TR200103216T2 (tr) Pirimidinon bileşimleri
IS2130B (is) Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
EE200000446A (et) Follikulaarsete lümfoomide ravi lümfotoksiini (LT) raja inhibiitorite abil
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
IL139144A0 (en) Mycobacterial inhibitors
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
AU2013204147B2 (en) Treatment of TNFalpha related disorders

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150129